Skip to main content
OpenTrials
Completed

NCT Number: NCT00204776

XELOX for Metastatic Breast Cancer

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Wisconsin

Madison, Wisconsin, 53792, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • preserved organ function
  • good performance status
  • no more than one prior therapy
  • no active brain metastasis

Exclusion criteria

  • No prior capecitabine or oxaliplatin
  • no con-current therapy

Treatment and study plan

Capecitabine and Oxaliplatin

Drug

Primary outcomes

  1. Overall response rate

Secondary outcomes

  1. Toxicity

  2. Time to progression

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Collaborators

  • Sanofi

Registry information

Official study title

A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer

Important dates

Study start
2005
Study completion
2006
First posted
Sep 20, 2005
Registry last updated
Dec 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.